Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Barry D. Quart
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 64
- Beta
- -0.22
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -24.88
Financials
Revenue
$0.00-100.0%Net Income
$-16.15MEBITDA
$-16.31MFree Cash Flow
$-807.0KEPS (diluted)
$-0.26Shares Outstanding (diluted)
62.97M+12.8%Operating Expenses
$17.05MCash & Debt
$19.49MReturn of Capital
$0.00Revenue by Segment (annual)
$110.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $64.0K | $-55.48M | $-1.00 |
| 2024 | $26.03M | $-15.63M | $-0.28 |
| 2023 | $0.00 | $-62.11M | $-1.08 |
| 2022 | $0.00 | $-118.09M | $-14.50 |
| 2021 | $0.00 | $-202.27M | $-25.00 |
| 2020 | $0.00 | $-119.37M | $-14.45 |
| 2019 | $0.00 | $-24.46M | $-3.02 |
Valuation
CNTBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·6d ago·Neutral
Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update – Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
View source ↗ - Newszacks.com·31d ago·Neutral
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newszacks.com·34d ago·Negative
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
View source ↗ - Newsmarketbeat.com·49d ago·Negative
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failures during the month after an exacerbation.
View source ↗ - Newsbenzinga.com·53d ago·Negative
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
View source ↗ - Newsbenzinga.com·68d ago·Neutral
Why Is Connect Biopharma Stock Trading Lower on Tuesday? Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
View source ↗
Earnings
Tue, Mar 30(in 4 months)
Consensus estimate $-0.19 per share
Typical surprise +2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.26 vs $-0.27beat
- Mon, Nov 16$-0.26 vs $-0.13miss
- Wed, Aug 12$-0.27 vs $-0.31beat
- Tue, May 12$-0.34 vs $-0.29miss
- Tue, Mar 31$-0.27 vs $-0.30beat
- Wed, Nov 12$-0.04 vs $-0.03miss
Estimates and results for CNTB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNTB officers and directors.
- Bought
- $4.4m
- Sold
- —
2 trades
0 trades
- Huang Jamesbought
- Huang Jamesbought
44 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CNTB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
